CPIX Fundamental Analysis - CUMBERLAND PHARMACEUTICALS

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to CPIX. CPIX was compared to 195 industry peers in the Pharmaceuticals industry. While CPIX seems to be doing ok healthwise, there are quite some concerns on its profitability. CPIX has a valuation in line with the averages, but it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year CPIX was profitable.

In the past year CPIX had a positive cash flow from operations.

CPIX had negative earnings in each of the past 5 years.

CPIX had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of CPIX (-4.68%) is better than 75.90% of its industry peers.

The Return On Equity of CPIX (-11.43%) is better than 76.92% of its industry peers.

		Industry Rank	Sector Rank
ROA	-4.68%
ROE	-11.43%
ROIC	N/A

ROA(3y)-7.42%

ROA(5y)-5.97%

ROE(3y)-21.64%

ROE(5y)-16.04%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of CPIX (84.33%) is better than 90.26% of its industry peers.

CPIX's Gross Margin has been stable in the last couple of years.

The Profit Margin and Operating Margin are not available for CPIX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	84.33%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.33%

GM growth 5Y1.04%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CPIX does not have a ROIC to compare to the WACC, probably because it is not profitable.

CPIX has less shares outstanding than it did 1 year ago.

The number of shares outstanding for CPIX has been reduced compared to 5 years ago.

CPIX has a worse debt/assets ratio than last year.

2.2 Solvency

CPIX has an Altman-Z score of 0.85. This is a bad value and indicates that CPIX is not financially healthy and even has some risk of bankruptcy.

CPIX has a Altman-Z score (0.85) which is comparable to the rest of the industry.

The Debt to FCF ratio of CPIX is 1.00, which is an excellent value as it means it would take CPIX, only 1.00 years of fcf income to pay off all of its debts.

CPIX's Debt to FCF ratio of 1.00 is amongst the best of the industry. CPIX outperforms 95.38% of its industry peers.

A Debt/Equity ratio of 0.18 indicates that CPIX is not too dependend on debt financing.

The Debt to Equity ratio of CPIX (0.18) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	1
Altman-Z	0.85

ROIC/WACCN/A

WACC9.16%

2.3 Liquidity

CPIX has a Current Ratio of 1.25. This is a normal value and indicates that CPIX is financially healthy and should not expect problems in meeting its short term obligations.

CPIX has a worse Current ratio (1.25) than 77.95% of its industry peers.

CPIX has a Quick Ratio of 1.09. This is a normal value and indicates that CPIX is financially healthy and should not expect problems in meeting its short term obligations.

CPIX's Quick ratio of 1.09 is on the low side compared to the rest of the industry. CPIX is outperformed by 72.82% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.25
Quick Ratio	1.09

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CPIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 550.00%, which is quite impressive.

Looking at the last year, CPIX shows a small growth in Revenue. The Revenue has grown by 5.82% in the last year.

The Revenue has been growing slightly by 1.95% on average over the past years.

EPS 1Y (TTM)550%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%420%

Revenue 1Y (TTM)5.82%

Revenue growth 3Y1.71%

Revenue growth 5Y1.95%

Sales Q2Q%37.76%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 26.23, which means the current valuation is very expensive for CPIX.

80.51% of the companies in the same industry are more expensive than CPIX, based on the Price/Earnings ratio.

CPIX is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.28, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	26.23
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CPIX is valued cheaper than 81.54% of the companies in the same industry.

Based on the Price/Free Cash Flow ratio, CPIX is valued cheaply inside the industry as 90.26% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	9.74
EV/EBITDA	14.41

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CPIX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CUMBERLAND PHARMACEUTICALS

NASDAQ:CPIX (7/2/2025, 5:20:00 PM)

After market: 3.32 -0.09 (-2.64%)

3.41

-0.08 (-2.29%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-06 2025-05-06/amc

Earnings (Next)08-04 2025-08-04

Inst Owners28.76%

Inst Owner Change132.35%

Ins Owners3.45%

Ins Owner Change0%

Market Cap51.01M

Analysts43.33

Price TargetN/A

Short Float %0.78%

Short Ratio1.16

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	26.23
Fwd PE	N/A
P/S	1.24
P/FCF	9.74
P/OCF	9.41
P/B	1.78
P/tB	4.74
EV/EBITDA	14.41

EPS(TTM)0.13

EY3.81%

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.35

FCFY10.26%

OCF(TTM)0.36

OCFY10.63%

SpS2.75

BVpS1.92

TBVpS0.72

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-4.68%
ROE	-11.43%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	84.33%
FCFM	12.74%

ROA(3y)-7.42%

ROA(5y)-5.97%

ROE(3y)-21.64%

ROE(5y)-16.04%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y1.33%

GM growth 5Y1.04%

F-Score7

Asset Turnover0.59

Health

		Industry Rank	Sector Rank
Debt/Equity	0.18
Debt/FCF	1
Debt/EBITDA	1.78
Cap/Depr	3.02%
Cap/Sales	0.46%
Interest Coverage	N/A
Cash Conversion	184.56%
Profit Quality	N/A
Current Ratio	1.25
Quick Ratio	1.09
Altman-Z	0.85

F-Score7

WACC9.16%

ROIC/WACCN/A

Cap/Depr(3y)16.58%

Cap/Depr(5y)20.37%

Cap/Sales(3y)2.19%

Cap/Sales(5y)2.64%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)550%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%420%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)5.82%

Revenue growth 3Y1.71%

Revenue growth 5Y1.95%

Sales Q2Q%37.76%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y50.05%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y5.15%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-24.53%

OCF growth 3YN/A

OCF growth 5YN/A

CUMBERLAND PHARMACEUTICALS (CPIX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens